Keros Therapeutics (KROS) Equity Average (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Equity Average data on file, last reported at $503.4 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 8.84% year-over-year to $503.4 million; the trailing twelve-month figure through Dec 2025 stood at $503.4 million (down 8.84% YoY), and the FY2025 full-year result was $437.3 million, down 3.22% from the prior year.
• Equity Average for Q4 2025 stood at $503.4 million, down from $705.2 million in the prior quarter.
• Across five years, Equity Average topped out at $717.8 million in Q2 2025 and bottomed at $217.4 million in Q2 2022.
• The 5-year median for Equity Average is $315.1 million (2023), against an average of $380.4 million.
• The widest annual swing landed in 2021, when Equity Average jumped 1251.11%; it then decreased 10.19% in 2022.
• A 5-year view of Equity Average shows it stood at $230.8 million in 2021, then advanced by 12.3% to $259.2 million in 2022, then advanced by 21.14% to $314.0 million in 2023, then jumped by 75.84% to $552.2 million in 2024, then retreated by 8.84% to $503.4 million in 2025.
• The last three Equity Average figures came in at $503.4 million (Q4 2025), $705.2 million (Q3 2025), and $717.8 million (Q2 2025), per Business Quant data.

Peer Comparison